Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg twice per day, or 200 mg twice per day. Enhanced...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Gerds, AT, Savona, MR, Scott, BL, Talpaz, M, Egyed, M, Harrison, CN, Yacoub, A, Vannucchi, A, Mead, AJ, Kiladjian, J-J, O'Sullivan, J, García-Gutiérrez, V, Bose, P, Rampal, RK, Miller, CB, Palmer, J, Oh, ST, Buckley, SA, Mould, DR, Ito, K, Tyavanagimatt, S, Smith, JA, Roman-Torres, K, Devineni, S, Craig, AR, Mascarenhas, JO
Định dạng:	Journal article
Ngôn ngữ:	English
Được phát hành:	American Society of Hematology 2020

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

Những quyển sách tương tự